|
1. Werner CA. The older population: 2010. 2010 Census briefs. http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Published November 2011. Accessed May 6, 2012.
2. Gilchrest BA. Skin aging and photoaging: an overview. J Am Acad Dermatol 1989;21:610–613.
3. Tindall JP, Smith JG Jr. Skin lesions of the aged and their association with internal changes. JAMA 1963;186:1039–1042.
4. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005;1:221–235.
5. Kligman AM. Perspectives and problems in cutaneous gerontology. J Invest Dermatol 1979;73:39–46.
6. Branchet MC, Boisnic S, Frances C, et al. Skin thickness changes in normal aging skin. Gerontology 1990;36:28–35.
7. Elias PM, Ghadially R. The aged epidermal permeability barrier: basis for functional abnormalities. Clin Geriatr Med 2002;18:103–120.
8. Chang E, Yang J, Nagavarapu U, et al. Aging and survival of cutaneous microvasculature. J Invest Dermatol 2002;118:752–758.
9. Tsuchida Y. The effect of aging and arteriosclerosis on human skin blood flow. J Dermatol Sci 1993;5:175–181.
10. Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002;138:1462–1470.
11. Chung JH, Eun HC. Angiogenesis in skin aging and photoaging. J Dermatol 2007;34:593–600.
12. Reddy VP, Obrenovich ME, Atwood CS, et al. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 2002;4:191–209.
13. Walcher D, Marx N. Advanced glycation end products and C-peptidemodulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol 2009;31:103–111.
14. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. ClinDiabetes 2003;21:186–187.
15. Pageon H. Reaction of glycation and human skin: the effects on the skin and its components, reconstructed skin as a model. Pathologie-biologie 2010;58:226–231.
16. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J ClinDermatol 2001;2:143–150.
17. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872–881.
18. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009;89:339–350.
19. Ward JR, Bernhard JD. Willan's itch and other causes of pruritus in the elderly. Int J Dermatol 2005;44:267–273.
20. Roberts WE. Dermatologic problems of older women. Dermatol Clin 2006;24:271–280.
21. Reich A, Stander S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol 2009;89:236–244.
22. Reich A, Stander S, Szepietowski JC. Pruritus in the elderly. ClinDermatol 2011;29:15–23.
23. Elmariah SB, Lerner EA. Topical therapies for pruritus. Semin Cutan MedSurg 2011;30:118–126.
24. Hercogova J. Topical anti-itch therapy. Dermatol Ther 2005;18:341–343.
25. Pierard GE, Quatresooz P. What do you mean by eczema craquele? Dermatology 2007;215:3–4.
26. Sparsa A, Boulinguez S, Liozon E, et al. Predictive clinical features of eczema craquele associated with internal malignancy. Dermatology 2007;215:28–35.
27. Norman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther 2003;16:254–259.
28. Rogers J, Harding C, Mayo A. Stratum corneum lipids: the effect of ageing and the seasons. Arch Dermatol Res 1996;288:765–770.
29. Rawlings VA, Watkinson, A, Rogers J, et al. Abnormalities in stratum corneum structure, lipid composition, and desmosome degradation in soap-induced winter xerosis. J Cosmet Sci 1994;45:203–220.
30. Noiles K, Vender R. Are all seborrheic keratoses benign? Review of the typical lesion and its variants. J Cutan Med Surg 2008;12:203–210.
31. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008;6:664–677.
32. Izikson L, Sober AJ, MihmMCJr, et al. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. Arch Derm 2002;138:1562–1566.
33. Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Derm 2011;29:541–547.
34. LCD for removal of benign skin lesions (L27362). Contractor information. http://www.medicarenhic.com/pa/policies/Removal%20of%20Benign%20Skin%20Lesions%20%28L27362%29.pdf. Accessed May 6, 2012.
35. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009;109(6 suppl 2):S13YS17.
36. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. ClinGeriatr Med 2007;23:615–632.
37. Farage MA, Miller KW, Berardesca E, et al. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009;10:73–86.
38. Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. DrugsAging 2007;24:1–19.
39. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160–166.
40. Voelker R. FDA expands age range for shingles vaccine. JAMA 2011;305:1526.
41. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–2284.
42. Brand CU, Hunziker T, Yawalkar N, et al. IL-1 beta protein in human skin lymph does not discriminate allergic from irritant contact dermatitis. Contact Dermatitis 1996;35:152–156.
43. Buckley DA, Rycroft RJ, White IR, et al. The frequency of fragrance allergy in patch-tested patients increases with their age. Br J Dermatol 2003;149:986–989.
44. Saap L, Fahim S, Arsenault E, et al Contact sensitivity in patients with leg ulcerations: a North American study. Arch Dermatol 2004;140:1241–1246.
45. Balato A, Balato N, Di Costanzo L, et al. Contact sensitization in the elderly. Clin Dermatol 2011;29:24–30.
46. Piaserico S, Larese F, Recchia GP, et al. Allergic contact sensitivity in elderly patients. Aging Clin Exp Res 2004;16:221–225.
47. Prakash AV, Davis MD. Contact dermatitis in older adults: a review of the literature. Am J Clin Dermatol 2010;11:373–381.
48. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010;10:CD002292.
49. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011;147:286–291.
50. Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2012 March 4 [epub ahead of print].
51. Iwashita K, Matsuyama T, Akasaka E, et al. The incidence of internal malignancies in autoimmune bullous diseases. Tokai J Exp Clin Med 2007;32:42–47.
52. Song HJ, Han SH, Hong WK, et al. Paraneoplastic bullous pemphigoid: clinical disease activity correlated with enzyme-linked immunosorbent assay index for the NC16A domain of BP180. J Dermatol 2009;36:66–68.
53. Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: from bench to bedside. Drugs 2005;65:905–926.
54. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008;59:582–588.
55. Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg 2008;47:1015–1021.
56. Karthikesalingam A, Young EL, Hinchliffe RJ, et al. A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2011;41:554–565.
57. Kirsner RS, Pardes JB, Eaglstein WH, et al. The clinical spectrum of lipodermatosclerosis. J Am Acad Dermatol 1993;28:623–627.
58. Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther 2010;23:375–388.
59. O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2009;1:CD000265.
60. Baldursson B, Sigurgeirsson B, Lindelof B. Venous leg ulcers and squamous cell carcinoma: a large-scale epidemiological study. Br JDermatol 1995;133:571–574.
61. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463Ye654.
62. Hafner J, Schaad I, Schneider E, et al. Leg ulcers in peripheral arterial disease (arterial leg ulcers): impaired wound healing above the threshold of chronic critical limb ischemia. J Am Acad Dermtol 2000;43:1001–1008.
63. Lewis KG,Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007;127:2323–2327.
64. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007;60:32–40.
65. Wei-Passanese EX, Han J, LinW, et al. Geographical variation in residence and risk of multiple nonmelanoma skin cancers in US women and men. Photo Photobiol 2012;88:483–489.
66. Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol 2011;50:645–658.
67. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007;1:CD003412.
68. Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for nonmetastatic squamous cell carcinoma of the skin. Cochrane DatabaseSyst Rev 2010;4:CD007869.
69. Martin GM. Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations. J Dermatol Treat 2011;22:288–297.
70. Davis N. Modern concepts of melanoma and its management. Ann PlastSurg 1978;1:628–629.
71. Dennis LK, Vanbeek MJ, Beane Freeman LE, et al. Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann Epidemiol 2008;18:614–627.
|
